CRISPR-based rapid and ultra-sensitive diagnostic test for Mycobacterium tuberculosis

Area of Science:

• Molecular diagnostics
• Infectious disease detection
• CRISPR-based technologies

Background:

• Tuberculosis (TB) diagnosis requires rapid and simple methods.
• CRISPR systems show promise for infectious disease detection.
• The diagnostic utility of CRISPR for Mycobacterium tuberculosis complex (MTB) was previously unexplored.

Purpose of the Study:

• To develop and evaluate a rapid CRISPR-based assay for TB detection.
• To assess the diagnostic performance of the CRISPR-MTB test in direct clinical samples.
• To compare the CRISPR-MTB test against culture and GeneXpert MTB/RIF (Xpert) assays.

Main Methods:

• Development of a novel CRISPR-based assay for MTB detection.
• Retrospective cohort study involving 179 patients.
• Evaluation of the CRISPR-MTB test on various direct clinical samples, comparing results with culture and Xpert.

Main Results:

• The CRISPR-MTB test demonstrated high sensitivity, approaching single-copy detection.
• It requires less sample input and has a shorter turnaround time than Xpert.
• In a clinical cohort, the CRISPR-MTB test showed superior sensitivity (79%) compared to culture (33%) and Xpert (66%), with high specificity (98%).

Conclusions:

• The CRISPR-MTB test offers improved diagnostic performance over culture and Xpert for both pulmonary and extra-pulmonary TB.
• The assay is highly sensitive, specific, rapid, and requires minimal sample input.
• CRISPR-MTB holds significant potential as a novel diagnostic tool for tuberculosis.